Medical advances, particularly technological and pharmaceutical, are continually increasing, and this pattern is likely to continue. In contrast to this technological and pharmaceutical expansion, the reality of a global recession and the need to cut costs are universal health-care challenges. Herein the authors review the approximate cost estimates for a proven strategy to manage colorectal peritoneal metastases, namely cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy and different tools government or heath care providers use in deciding which treatments to fund and remunerate.
Deep Epigastric Lymph Nodes Implication in Patients’ Recurrence Pattern After Cytoreductive Surgery in Colorectal Peritoneal Metastases
